Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. 2005

Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
Neuropharma, S.A., Avda. de La Industria 52, 28760 Tres Cantos, Madrid, Spain.

New dual binding site acetylcholinesterase (AChE) inhibitors have been designed and synthesized as new potent drugs that may simultaneously alleviate cognitive deficits and behave as disease-modifying agents by inhibiting the beta-amyloid (A beta) peptide aggregation through binding to both catalytic and peripheral sites of the enzyme. Particularly, compounds 5 and 6 emerged as the most potent heterodimers reported so far, displaying IC50 values for AChE inhibition of 20 and 60 pM, respectively. More importantly, these dual AChE inhibitors inhibit the AChE-induced A beta peptide aggregation with IC50 values 1 order of magnitude lower than that of propidium, thus being the most potent derivatives with this activity reported up to date. We therefore conclude that these compounds are very promising disease-modifying agents for the treatment of Alzheimer's disease (AD).

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002091 Butyrylcholinesterase An aspect of cholinesterase (EC 3.1.1.8). Pseudocholinesterase,Benzoylcholinesterase,Butyrylthiocholinesterase
D002417 Cattle Domesticated bovine animals of the genus Bos, usually kept on a farm or ranch and used for the production of meat or dairy products or for heavy labor. Beef Cow,Bos grunniens,Bos indicus,Bos indicus Cattle,Bos taurus,Cow,Cow, Domestic,Dairy Cow,Holstein Cow,Indicine Cattle,Taurine Cattle,Taurus Cattle,Yak,Zebu,Beef Cows,Bos indicus Cattles,Cattle, Bos indicus,Cattle, Indicine,Cattle, Taurine,Cattle, Taurus,Cattles, Bos indicus,Cattles, Indicine,Cattles, Taurine,Cattles, Taurus,Cow, Beef,Cow, Dairy,Cow, Holstein,Cows,Dairy Cows,Domestic Cow,Domestic Cows,Indicine Cattles,Taurine Cattles,Taurus Cattles,Yaks,Zebus
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005470 Fluorometry An analytical method for detecting and measuring FLUORESCENCE in compounds or targets such as cells, proteins, or nucleotides, or targets previously labeled with FLUORESCENCE AGENTS. Fluorimetry,Fluorometric Analysis,Analysis, Fluorometric
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000110 Acetylcholinesterase An enzyme that catalyzes the hydrolysis of ACETYLCHOLINE to CHOLINE and acetate. In the CNS, this enzyme plays a role in the function of peripheral neuromuscular junctions. EC 3.1.1.7. Acetylcholine Hydrolase,Acetylthiocholinesterase,Hydrolase, Acetylcholine
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia

Related Publications

Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
January 2013, Bioorganic & medicinal chemistry,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
September 2017, Bioorganic & medicinal chemistry letters,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
October 2017, European journal of medicinal chemistry,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
May 2013, Die Pharmazie,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
January 2013, Bioorganic & medicinal chemistry,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
October 2002, Organic letters,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
December 2016, Bioorganic chemistry,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
September 2019, Neuropharmacology,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
January 2019, ACS chemical neuroscience,
Pilar Muñoz-Ruiz, and Laura Rubio, and Esther García-Palomero, and Isabel Dorronsoro, and María del Monte-Millán, and Rita Valenzuela, and Paola Usán, and Celia de Austria, and Manuela Bartolini, and Vincenza Andrisano, and Axel Bidon-Chanal, and Modesto Orozco, and F Javier Luque, and Miguel Medina, and Ana Martínez
September 2001, Mini reviews in medicinal chemistry,
Copied contents to your clipboard!